Evolus (EOLS) Other financing activities (2018)

Evolus (EOLS) posted Other financing activities of -$11.4 million for Q4 2018, down 200.0% on a QoQ basis from $11.4 million in Q3 2018.

Evolus (EOLS) Other financing activities (2018) Analysis & Trends

Evolus' Other financing activities history runs 1 years deep, the most recent figure standing at -$11.4 million for Q4 2018.

Quarterly Other financing activities changed N/A year-over-year to -$11.4 million in Q4 2018, while the trailing twelve-month figure through Dec 2019 was $30000.0 (down 99.95% YoY) and the FY2024 annual result came in at $4.9 million, up 2013.42% from the prior year.
Other financing activities was -$11.4 million for Q4 2018 at Evolus, down from $11.4 million in the prior quarter.
Across five years, Other financing activities topped out at $56.3 million in Q1 2018 and bottomed at -$11.4 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn
10	Evolus	390.47 Mn	340.68 Mn	48.90 Mn

Download Data